Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC

The 2-year investigator-assessed event-free survival rate in the intent-to-treat population of patients with high-risk head and neck squamous cell carcinoma was 67.4% with atezolizumab.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

A biologics license application for subcutaneous amivantamab combined with recombinant human hyaluronidase has been submitted to the FDA for NSCLC indications.

In this episode of Targeted Talks, Aaron Lisberg, MD, discusses results from the phase 3 TROPION-Lung01 study of datopotamab in advanced or metastatic non–small cell lung cancer.

Amivantamab plus chemotherapy significantly prolonged progression-free survival in patients with EGFR-mutant advanced non–small cell lung cancer.

Patients with chronic myeloid leukemia can have a near-normal life expectation when treated with BCR::ABL1 tyrosine kinase inhibitors.